Fluoroquinolone and no risk of Achilles-tendinopathy in childhood pneumonia under eight years of age—a nationwide retrospective cohort

BACKGROUND: The emergence of macrolide-resistant Mycoplasma pneumoniae pneumonia (MRMP) has made its treatment challenging. A few guidelines have recommended fluoroquinolones (FQs) as second-line drugs of choice for treating MRMP in children under the age of eight, but concerns about potential adver...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yunsun, Park, Gun Woo, Kim, Sangyoung, Moon, Hui Jeong, Won, Sungho, Chung, Wankyo, Yang, Hyeon-Jong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264711/
https://www.ncbi.nlm.nih.gov/pubmed/34277036
http://dx.doi.org/10.21037/jtd-20-2256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264711/
https://www.ncbi.nlm.nih.gov/pubmed/34277036
http://dx.doi.org/10.21037/jtd-20-2256

Ejemplares similares